ClinicalTrials.gg
Not yet recruitingNCT07658027Updated Nov 3, 2026

Vestibular Stimulation in Sleep for Neurorehabilitation Patients

An interventional study of Somnomat - rocking bed providing vestibular stimulation during sleep in Memory Deficit Aquired Due to the Disease, e.g. Stroke, Neurodegeneration, Inflammatory Disease of CNS, Traumatic Brain Injury, sponsored by Cereneo AG. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionBrain Injuries, TraumaticRegistry: Nerve DegenerationReclassifiedWhy we changed it
Registry
Nerve Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Injuries, Traumatic
Why
  1. Nerve Degeneration is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Brain Injuries, Traumatic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Cereneo AG · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Brain Injuries, Traumatic with a site in Switzerland — 6 open to participants now, 8 under way, 2 of them phase 3. Brain Injuries, Traumatic · Switzerland.

Planned enrollment
13th of 23
20 · median 25
Started
2027
the only one that year
No phase
18 of 31
5 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Cereneo AG

Among the 31 studies in Brain Injuries, Traumatic with a site in Switzerland, this one is the 13th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2027, is one of 18 with no phase, and was the 31st registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

6 of the 31 studies in Brain Injuries, Traumatic with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Brain Injuries, Traumatic with a site in Switzerland, or all of them as a file.
02

Study summary

  1. Why are we conducting this study? You are a patient of the neurorehabilitation clinic with one of the therapy focuses on memory and learning. Neuropsychological training is a standard therapeutic approach in this case. It is also known that better quality of sleep may not only improve the well-being of individuals but also enhance memory and learning. In this study, we investigate how the rocking bed influences sleep duration and quality, whether it has additional effects on memory and learning, and if it is well-tolerated and safe.
  2. What do you have to do if you decide to participate?

    Participation in this study will take 4-6 weeks depending on your group. All study assess-ments will be done during your stay in the clinic. If you agree to participate, you will be asked to:

    • Undergo an overnight sleep assessment (polysomnography) 3 or 4 times during the study, depending on the group you are allocated
    • Sleep in the rocking bed for 14 consecutive nights
    • Answer questionnaires related to your sleep If you decide to participate, you will be randomly assigned to one of 2 groups. Participants of Group 1 will be asked to use the rocking bed for the first 2 weeks after randomization. Participants of Group 2 will be using the rocking bed in weeks 3-4 after randomization.
  3. What are the benefits and risks associated with participation? Benefits Based on the previous studies of the rocking bed, it may improve your sleep quality and cognitive function. However, since its effectiveness for neurorehabilitation patients has not yet been established, any individual benefit cannot be guaranteed. It is possible that you will help future neurorehabilitation patients with your participation by generating data on the effectiveness and safety of the rocking bed in long-term use.

Risks

The investigational rocking bed has not yet been certified in Switzerland. Its use for neurorehabilitation patients is new and has not yet been tested. We may not yet know all the possible risks and side effects of the tested device. So far, the following risks and discomforts should be considered:

  • A small risk of falling when getting out of bed at night
  • Risk of unauthorized personal data access
  • Temporary discomfort due to the study environment or equipment
03

Conditions studied

  • Memory Deficit Aquired Due to the Disease, e.g. Stroke, Neurodegeneration, Inflammatory Disease of CNS, Traumatic Brain Injury

Browse trials for

Keywords

  • stroke
  • neurodegeneration
  • inflammatory disease of CNS
  • traumatic brain injury
04

In context

Brain Injuries, Traumatic Reclassified

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

This study's planned enrollment of 20 is below the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Cereneo AG is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within Brain Injuries, Traumatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nerve Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neurorehabilitation clinic patients with focus in learning or memory in neuropsychological training
  • Age > 18 years
  • Signed
  • Smokers and non-smokers
  • Patients of all ethnical backgrounds

Exclusion criteria

Exclusion Criteria:

  • Disorders of the vestibular system or sensitivity to motion sickness (Motion Sickness Susceptibility Questionnaire \<10 (Golding, 2006)
  • Hygiene-relevant infections requiring sanitization of patient care equipment: active or their asymptomatic carrying (as surface material of the rocking bed is not eligible
  • Cognitive or motor deficit presenting a risk for self-use of the rocking bed at night: utmostly, creating the risk of falls during embarking and disembarking from the bed
  • Transfer deficits. >1 persons are needed for transfer
  • Short planned duration of stay \<4 weeks
  • Pregnancy or lactation
  • Refusal to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants of Group 1 will be using the rocking bed for the first 2 weeks after randomization.

    Device: Somnomat - rocking bed providing vestibular stimulation during sleep

  • Experimental
    Group 2

    Participants of Group 2 will be using the rocking bed in weeks 3-4 after randomization

    Device: Somnomat - rocking bed providing vestibular stimulation during sleep

Interventions

  • DeviceSomnomat - rocking bed providing vestibular stimulation during sleep

    Rocking is known to have a sedative and sleep-promoting effect: parents are rocking their newborns and infants to facilitate sleep, and many individuals experience increased sleepiness during passive motion, such as in transport. Recent engineering solutions have enabled the development of rocking beds and wearable devices simulating motion. Previous studies of rocking bed in healthy humans have shown that the use of these devices can improve sleep. Furthermore, improvement of sleep can mediate positive effects of rocking on memory, learning. However, their safety, effectiveness and applicability should be tested in research and clinical setting In this study, we are therefore investigating whether the rocking bed is efficient for sleep, if it has complementary effects on memory while using together with the cognitive training. In addition we are testing, if the device is well tolerated. The investigational device is not yet approved in Switzerland.

07

What researchers measure

Primary outcomes

  1. Objective total sleep time (TST)

    measured with polysomnography

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

Secondary outcomes

  1. objective sleep efficiency (SE)

    measured by PSG

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  2. objective sleep latency (SL)

    measured by PSG

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  3. objective wake after sleep onset (WASO)

    measured by PSG

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  4. total time in bed (TIB)

    measured by PSG

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  5. Objective number of awakenings

    measured by PSG

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  6. absolute duration of N1

    obtained from PSG, measured in min

    Time frame: Objective sleep measures (PSG) are obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  7. proportion of N1

    obtained from PSG, measured in %

    Time frame: obtained pre- and post-intervention phases at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  8. absolute duration of N2

    obtained from PSG, measured in min

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  9. Proportion of N2

    obtained from PSG, measured in %

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  10. absolute duration of N3 stage

    obtained from PSG, measured in min

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  11. Proportion of N3 stage

    obtained from PSG

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  12. absolute duration of REM phase

    obtained from PSG, measured in min

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  13. Proportion of REM phase

    obtained from PSG, measured in %

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  14. Total number of sleep spindles

    obtained from PSG, countable variable

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  15. Density of sleep spindles

    obtained from PSG, index calculated as number of events per 1 h in N2 stage

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  16. Slow wave activity

    obtained from PSG, power of delta activity per unit of time

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  17. subjective sleep effectiveness

    obtained from a daily sleep diary, measured in %

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.

  18. subjective sleep latency

    obtained from daily sleep diary

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.

  19. subjective total sleep time

    obtained from daily sleep diary

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.

  20. Subjective number of awakenings

    obtained from daily sleep diary

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.

  21. subjective wake after sleep onset (WASO)

    obtained from daily sleep diary

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0-4 for Group 1 and Week 0-6 for Group 2.

  22. PSQI score

    Pittsburgh Sleep Quality Index (PSQI), a validated self-report measure of sleep quality over the past month. The PSQI yields a global score (0-21), with higher scores indicating poorer sleep quality.

    Time frame: subjective sleep quality are obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: Week 0, Week 2, Week 4 for Groups 1 and 2; Week 6 for Group 2.

  23. Verbal memory

    Neuropsychological test: Auditiv-Verbaler Lern- und Gedächtnistest (AVLGT) for German-speaking participants, or its English adaptation, Verbal Learning and memory test (VLMT) the consisting of 15 words with different word lists in order to avoid learning effect. Assessments are conducted weekly

    Time frame: obtained between 03.08.2026 and 31.07.2027 at pre- and post-intervention phases and at follow up: between Week 0 and Week 4 for Group 1 and between Week 0 and Week 6 for Group 2.

Other outcomes

  1. Age

    measured in years

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

  2. Gender

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

  3. Race

    categorical variable

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

  4. Years of education

    measured in years

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

  5. Main diagnosis

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

  6. Disease onset

    years ago

    Time frame: Collected once at baseline (Week 0) between 03.08.2026 and 31.07.2027

  7. comorbid sleep disordes

    categorical variable

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

  8. Medications

    categorical variable

    Time frame: Collected at baseline (Week 0) between 03.08.2026 and 31.07.2027

08

Study locations

1 site
  • cereneo Schweiz AG, Hertensteinstrasse 162 CH-6353
    Weggis, 6353, Switzerland
09

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2028, 12 months later.

Of 467 interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 64. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start Aug 2026 → Feb 2027, primary completion Jul 2027 → Feb 2028 and completion Dec 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2026
First posted
Jun 18, 2026
StartEst.
Feb 3, 2027was Aug 2026
Primary completionEst.
Feb 29, 2028was Jul 2027
CompletionEst.
Dec 31, 2028was Dec 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 3, 2026→Feb 3, 2027
Nov 3, 2026
Primary completion
Jul 31, 2027→Feb 29, 2028
Nov 3, 2026
Study completion
Dec 31, 2027→Dec 31, 2028
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Start date Aug 3, 2026→Feb 3, 2027
    Primary completion Jul 31, 2027→Feb 29, 2028
    Study completion Dec 31, 2027→Dec 31, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07658027
Lead sponsor
Cereneo AG
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Feb 3, 2027 (estimated)
Primary completion
Feb 29, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Polina Pchelina, Ph.D
Contact
polina.pchelina@cereneo.ch
+41795765987

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion